vantuylen

[From OttawaCitizen, July 12, 2018] “MISSISSAUGA, Ontario — Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for Biktarvy™ (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. BIKTARVY combines the potency of a novel integrase strand […]

[From AIDSmap, July 11, 2018] “Research is urgently needed to provide clear recommendations on breastfeeding to mothers with HIV who have an undetectable viral load on antiretroviral treatment, a group of researchers say in the journal The Lancet HIV.” For more, click here.

[From Infectious Disease Advisor, July 10, 2018] “There is a substantial prevalence of vitamin D deficiency (<25 nmol/L) worldwide, with estimates of 5% to 15% in high-income countries; rates of vitamin D insufficiency (<75 nmol/L) range from 50% to 75%.1 In addition to its direct effects on bone pathologies,2 increasing evidence links vitamin D deficiency

[From Healio, July 6, 2018] “A 28-year-old man in Thailand appeared to have acquired multidrug-resistant HIV while on pre-exposure prophlyaxis, or PrEP, researchers reported. It is one of the few cases of PrEP failure with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and the first known reported case in a developing country, according to Donn J. Colby, MD,

[From National AIDS Trust, July 6, 2018] “In 2015, an HIV outbreak was detected amongst people who inject drugs (PWIDs) in Glasgow. Three years on the outbreak has still not been controlled, and over 100 PWIDs in Scotland have been diagnosed with HIV. Those diagnosed have complex needs and experience severe social exclusion, with 40%